Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Inclusion Criteria:

* Male or non-pregnant, non-lactating female ≥18 years of age (no maximum age).
* Diagnosis of wAIHA at least 3 months prior to screening with a direct antiglobulin test (DAT) ≥1 positive for immunoglobulin G (IgG)±C3, or a diagnosis of mixed autoimmune hemolytic anemia (AIHA) that is DAT positive for both IgG and C3, with a presence of a cold antibody with a thermal amplitude ≥30ºCelcius.
* Hemoglobin (Hgb) level ≤10.0 grams/deciliter (pre-transfusion).
* Evidence of classical complement pathway activation.
* Evidence of active hemolysis.
* Stable use of glucocorticoids and immunosuppressants are permitted.
* Vaccinations against encapsulated bacterial organisms within 5 years prior to screening or participant must be willing to receive prophylaxis against infections with encapsulated bacteria via vaccination and/or the use of prophylactic antibiotics in accordance with local standards of practice and/or guidelines.

Exclusion Criteria:

* Elevated aspartate aminotransferase or alanine aminotransferase levels \>2.5 times the upper limit of normal.
* Platelet count \<30 X 10\^9/liter.
* History of cold agglutinin disease.
* History of solid organ, bone marrow, or stem cell transplantation.
* History of splenectomy within the 3 months prior to screening.
* Received rituximab or other anti-CD20 monoclonal antibody \<3 months prior to screening.
* Intravenous immunoglobulin (IVIg) treatment within 3 months prior to screening or plasmapheresis or immunoadsorption treatment within 60 days prior to screening.
* Clinically significant, recent, or ongoing illness or medical condition, including coexistent autoimmune disorder, malignancy, HIV, hepatitis B virus, and hepatitis C virus.
* History of meningitis or septicemia within the past 2 years.
* Treatment with an investigational therapeutic agent within 30 days prior to screening.
* Hypersensitivity to any drug product or excipients used in this study or to previous IV medication administration.
* Body weight less than 50 kilograms (kg) or greater than 100 kg